Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Pfizer Inc.
Headquarters: New York, NY, United States of America
Website: http://www.pfizer.com
Year Founded: 1849
Status: Public
Industry Sector: HealthTechnology
CEO: Albert Bourla, PhD, DVM
Number Of Employees: 81,000
Enterprise Value: $198,031,000,000
PE Ratio: 18.15
Exchange/Ticker 1: NYSE:PFE
Exchange/Ticker 2: N/A
Latest Market Cap: $144,905,551,872
BioCentury | Mar 25, 2025
Deals
Novo buys into obesity triple mechanism; AZ deepens China ties: Deals Report
Plus: Dren Bio strikes $600M bispecific agreement with Sanofi, and more
BioCentury | Mar 21, 2025
Finance
Maxion, Ampersand, Latigo, Arbor raise private rounds: Finance Report
Plus: SV Health Investors hits $250M goal for second Dementia Discovery Fund
BioCentury | Mar 20, 2025
Regulation
Amvuttra’s label expansion lifts Alnylam toward five-year goals
Non-GAAP profitability in sight as RNAi therapeutic adds cardiomyopathy indication alongside previous amyloidosis approval
BioCentury | Mar 20, 2025
Data Byte
FDA’s new and supplemental approvals in February
Springworks gets priority review voucher for Gomekli, first NovoLog biosimilar reaches market, and more
BioCentury | Mar 17, 2025
Finance
With Medicxi’s backing, Curevo takes aim at Shingrix with $110M series B
Former GSK vaccines head Slaoui becomes chairman as Seattle start-up advances shingles shot that may confer tolerability benefit
BioCentury | Mar 15, 2025
Politics, Policy & Law
It’s been a year: BIO CEO Crowley’s plans for Trump 2.0
BIO is engaging Trump to protect and improve FDA, hoping to dodge tariffs, looking for paths to modify IRA and reinstate PRVs
BioCentury | Mar 14, 2025
Data Byte
Ten PDUFA dates on FDA’s March agenda
Upcoming decisions include a label expansion for Alnylam’s Amvuttra, a new siRNA therapy for hemophilia, and more
BioCentury | Mar 12, 2025
Deals
Chasing amylin: Must-have obesity target key to Roche-Zealand deal
Swiss pharma pays $1.7B upfront for Zealand’s petrelintide, adding obesity’s hottest target
BioCentury | Mar 12, 2025
Product Development
What Arvinas’ data say about target selection
Focusing on the crowded SERD space left little room for differentiation
BioCentury | Mar 7, 2025
Management Tracks
Abbas Kazimi succeeds Jeb Keiper as CEO of Nimbus
Plus: Jon Garay Alonso named CFO of Almirall, and updates from Certara and Immunai
Items per page:
1 - 10 of 9175